222 related articles for article (PubMed ID: 15704863)
1. Evidence of cellular immune activation in children with opsoclonus-myoclonus: cerebrospinal fluid neopterin.
Pranzatelli MR; Hyland K; Tate ED; Arnold LA; Allison TJ; Soori GS
J Child Neurol; 2004 Dec; 19(12):919-24. PubMed ID: 15704863
[TBL] [Abstract][Full Text] [Related]
2. Cerebrospinal fluid ACTH and cortisol in opsoclonus-myoclonus: effect of therapy.
Pranzatelli MR; Chun KY; Moxness M; Tate ED; Allison TJ
Pediatr Neurol; 2005 Aug; 33(2):121-6. PubMed ID: 16087057
[TBL] [Abstract][Full Text] [Related]
3. [Opsoclonus-myoclonus syndrome associated with non-metastatic neuroblastoma. Long-term survival. Study of the French Society of Pediatric Oncologists].
Plantaz D; Michon J; Valteau-Couanet D; Coze C; Chastagner P; Bergeron C; Nelken B; Martelli H; Peyroulet MC; Carpentier AF; Armari-Alla C; Pagnier A; Rubie H
Arch Pediatr; 2000 Jun; 7(6):621-8. PubMed ID: 10911528
[TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal fluid oligoclonal bands in childhood opsoclonus-myoclonus.
Pranzatelli MR; Slev PR; Tate ED; Travelstead AL; Colliver JA; Joseph SA
Pediatr Neurol; 2011 Jul; 45(1):27-33. PubMed ID: 21723456
[TBL] [Abstract][Full Text] [Related]
5. CCR7 signaling in pediatric opsoclonus-myoclonus: upregulated serum CCL21 expression is steroid-responsive.
Pranzatelli MR; Tate ED; McGee NR; Ransohoff RM
Cytokine; 2013 Oct; 64(1):331-6. PubMed ID: 23764550
[TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal fluid 5-hydroxyindoleacetic acid and homovanillic acid in the pediatric opsoclonus-myoclonus syndrome.
Pranzatelli MR; Huang Y; Tate E; Stanley M; Noetzel MJ; Gospe SM; Banasiak K
Ann Neurol; 1995 Feb; 37(2):189-97. PubMed ID: 7531417
[TBL] [Abstract][Full Text] [Related]
7. Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome.
Pranzatelli MR; Tate ED; Travelstead AL; Barbosa J; Bergamini RA; Civitello L; Franz DN; Greffe BS; Hanson RD; Hurwitz CA; Kalinyak KA; Kelfer H; Khakoo Y; Mantovani JF; Nicholson SH; Sanders JM; Wegner S
J Pediatr Hematol Oncol; 2006 Sep; 28(9):585-93. PubMed ID: 17006265
[TBL] [Abstract][Full Text] [Related]
8. CSF B-cell expansion in opsoclonus-myoclonus syndrome: a biomarker of disease activity.
Pranzatelli MR; Travelstead AL; Tate ED; Allison TJ; Verhulst SJ
Mov Disord; 2004 Jul; 19(7):770-777. PubMed ID: 15254934
[TBL] [Abstract][Full Text] [Related]
9. Paraneoplastic opsoclonus/myoclonus: B cells, T cells, both, or neither?
Posner JB
Neurology; 2004 May; 62(9):1466-7. PubMed ID: 15136666
[No Abstract] [Full Text] [Related]
10. Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: histopathologic features-a report from the Children's Cancer Group.
Cooper R; Khakoo Y; Matthay KK; Lukens JN; Seeger RC; Stram DO; Gerbing RB; Nakagawa A; Shimada H
Med Pediatr Oncol; 2001 Jun; 36(6):623-9. PubMed ID: 11344493
[TBL] [Abstract][Full Text] [Related]
11. Delayed, recurrent opsoclonus-myoclonus syndrome responding to plasmapheresis.
Armstrong MB; Robertson PL; Castle VP
Pediatr Neurol; 2005 Nov; 33(5):365-7. PubMed ID: 16243225
[TBL] [Abstract][Full Text] [Related]
12. Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies-a report from the Children's Cancer Group Study.
Rudnick E; Khakoo Y; Antunes NL; Seeger RC; Brodeur GM; Shimada H; Gerbing RB; Stram DO; Matthay KK
Med Pediatr Oncol; 2001 Jun; 36(6):612-22. PubMed ID: 11344492
[TBL] [Abstract][Full Text] [Related]
13. Long-term neurologic outcome in children with opsoclonus-myoclonus associated with neuroblastoma: a report from the Pediatric Oncology Group.
Russo C; Cohn SL; Petruzzi MJ; de Alarcon PA
Med Pediatr Oncol; 1997 Apr; 28(4):284-8. PubMed ID: 9078325
[TBL] [Abstract][Full Text] [Related]
14. Opsoclonus-myoclonus in Aicardi-Goutières syndrome.
Alburaiky S; Dale RC; Crow YJ; Jones HF; Wassmer E; Melki I; Boespflug-Tanguy O; Do Cao J; Gras D; Sharpe C
Dev Med Child Neurol; 2021 Dec; 63(12):1483-1486. PubMed ID: 34155623
[TBL] [Abstract][Full Text] [Related]
15. Opsoclonus-ataxia caused by childhood neuroblastoma: developmental and neurologic sequelae.
Mitchell WG; Davalos-Gonzalez Y; Brumm VL; Aller SK; Burger E; Turkel SB; Borchert MS; Hollar S; Padilla S
Pediatrics; 2002 Jan; 109(1):86-98. PubMed ID: 11773546
[TBL] [Abstract][Full Text] [Related]
16. [Cerebrospinal fluid neopterin levels in children with neurologic diseases].
Nakazawa T
No To Hattatsu; 1996 Jul; 28(4):291-8. PubMed ID: 8753127
[TBL] [Abstract][Full Text] [Related]
17. Technical and biochemical factors affecting cerebrospinal fluid 5-MTHF, biopterin and neopterin concentrations.
Verbeek MM; Blom AM; Wevers RA; Lagerwerf AJ; van de Geer J; Willemsen MA
Mol Genet Metab; 2008 Nov; 95(3):127-32. PubMed ID: 18722797
[TBL] [Abstract][Full Text] [Related]
18. Neopterin, biopterin, and nitric oxide concentrations in the cerebrospinal fluid of children with central nervous system infections.
Azumagawa K; Suzuki S; Tanabe T; Wakamiya E; Kawamura N; Tamai H
Brain Dev; 2003 Apr; 25(3):200-2. PubMed ID: 12689700
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Responsiveness to Reduced-Dose Rituximab in Corticotropin/Intravenous Immunoglobulin/Rituximab Combination Immunotherapy for Opsoclonus-Myoclonus Syndrome.
Pranzatelli MR; Tate ED; McGee NR; MacArthur CA
Pediatr Neurol; 2018 Aug; 85():71-75. PubMed ID: 30197220
[TBL] [Abstract][Full Text] [Related]
20. Improvement of neurological status and quality of life in children with opsoclonus myoclonus syndrome at long-term follow-up.
Catsman-Berrevoets CE; Aarsen FK; van Hemsbergen ML; van Noesel MM; Hakvoort-Cammel FG; van den Heuvel-Eibrink MM
Pediatr Blood Cancer; 2009 Dec; 53(6):1048-53. PubMed ID: 19672966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
